Empagliflozin

Overview

Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 ( SGLT-2 ) inhibitor with an IC 50 of 3.1 nM for human SGLT-2.

Application

Products | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > HER-2 Positive Breast Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Coronavirus Infection | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > SGLT

Product Information

• Catalog No.: HY-15409
• CAS No.: 864070-44-0
• Molecular Formula: C23H27ClO7
• Molecular Weight: 450.91
• Purity: 99.90%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.87 mg/mL (6.36 mM); Clear solution
• Availability: In-stock

Source

Original product source